Company Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type.
It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
The company was founded in 2002 and is based in Coral Gables, Florida.
| Country | United States |
| Founded | 2002 |
| IPO Date | Nov 8, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 167 |
| CEO | Richard John Daly M.B.A. |
Contact Details
Address: 355 Alhambra Circle, Suite 801 Coral Gables, Florida 33134 United States | |
| Phone | (305) 529-2522 |
| Website | catalystpharma.com |
Stock Details
| Ticker Symbol | CPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001369568 |
| CUSIP Number | 14888U101 |
| ISIN Number | US14888U1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Patrick J. McEnany | Co-Founder and Chairman |
| Richard John Daly M.B.A. | President, Chief Executive Officer and Director |
| Dr. Steven R. Miller Ph.D. | Executive Vice President, Chief Operating Officer and Chief Scientific Officer |
| Dr. Gary Ingenito M.D., Ph.D. | Chief Medical and Regulatory Officer |
| Jeffrey Del Carmen | Executive Vice President and Chief Commercial Officer |
| Michael W. Kalb CPA | Executive Vice President, Treasurer and Chief Financial Officer |
| Mary Coleman | Vice President and Head of Investor Relations |
| Brian Elsbernd J.D. | Chief Compliance Officer and Chief Legal Officer |
| Pete Curry Sr. | Vice President of Sales |
| Dr. Stanley Iyadurai M.D., Ph.D. | Senior Vice President of Medical Affairs and Drug Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | ARS | Filing |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2024 | 144 | Filing |
| Mar 27, 2024 | 144 | Filing |
| Mar 13, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 10-K | Annual Report |
| Feb 21, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |